MedCodeSearch
HCPCS Level II Current in October 2026

M1194

Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)

Release
October 2026
Effective
Official source (opens in a new tab)

Version History

How M1194 appears in each release imported from the official files, newest first.

  1. October 2026 Effective

    Current

    Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)

  2. July 2026 Effective

    Unchanged

    Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)

  3. April 2026 Effective

    Unchanged

    Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)

  4. January 2026 Effective

    Unchanged

    Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)

Data Source

Code information on this page is derived from the October 2026 HCPCS Level II files published by CMS.

Release
October 2026
Effective
Source file
october-2026-alpha-numeric-hcpcs-file.zip

Official HCPCS Level II source files (opens in a new tab)

MedCodeSearch is an independent reference service and is not affiliated with CMS, CDC, or the U.S. government.

Look up another code

Search ICD-10-CM, ICD-10-PCS and HCPCS Level II by code or description.